Back to News
Market Impact: 0.32
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Ardelyx expects nearly $500 million in 2026 revenue and projects profitability in 2027, driven by continued growth of IBS-C drug IBSRELA and hyperphosphatemia treatment XPHOZAH. The outlook signals meaningful commercial expansion for its two key products, although profitability remains more than a year away.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
ARDX0.62
More News
- Chip stocks snap back on multi-billion-dollar AI bet - AI Strategy got in early
- London neocloud Nscale takes its $1B loss to Wall Street
- Stock boom is fueling a ‘retirement party,’ economists say — what it means for workers
- Morgan Stanley warns of a 7% S&P 500 dip as rebound catalysts emerge
- Paramount Skydance stock in Focus as odds of Warner Bros deal closing rise
- Drug developer ADARx seeks $1.74 billion valuation in US IPO